FI106029B - Yhdistelmä -DNA-teknisten proteiinien parannettu aktivointi - Google Patents

Yhdistelmä -DNA-teknisten proteiinien parannettu aktivointi Download PDF

Info

Publication number
FI106029B
FI106029B FI920742A FI920742A FI106029B FI 106029 B FI106029 B FI 106029B FI 920742 A FI920742 A FI 920742A FI 920742 A FI920742 A FI 920742A FI 106029 B FI106029 B FI 106029B
Authority
FI
Finland
Prior art keywords
pro
seq
arg
met
lys
Prior art date
Application number
FI920742A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI920742A (fi
FI920742A0 (fi
Inventor
Carola Dony
Dorothea Ambrosius
Rainer Rudolph
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6425597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI106029(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of FI920742A0 publication Critical patent/FI920742A0/fi
Publication of FI920742A publication Critical patent/FI920742A/fi
Application granted granted Critical
Publication of FI106029B publication Critical patent/FI106029B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Adhesive Tapes (AREA)
  • Dental Preparations (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI920742A 1991-02-21 1992-02-20 Yhdistelmä -DNA-teknisten proteiinien parannettu aktivointi FI106029B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4105480A DE4105480A1 (de) 1991-02-21 1991-02-21 Verbesserte aktivierung von rekombinanten proteinen
DE4105480 1991-02-21

Publications (3)

Publication Number Publication Date
FI920742A0 FI920742A0 (fi) 1992-02-20
FI920742A FI920742A (fi) 1992-08-22
FI106029B true FI106029B (fi) 2000-11-15

Family

ID=6425597

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920742A FI106029B (fi) 1991-02-21 1992-02-20 Yhdistelmä -DNA-teknisten proteiinien parannettu aktivointi

Country Status (20)

Country Link
US (1) US5578710A (no)
EP (1) EP0500108B1 (no)
JP (1) JP2528232B2 (no)
KR (1) KR950014493B1 (no)
AT (1) ATE144284T1 (no)
AU (1) AU641081B2 (no)
CA (1) CA2061569C (no)
CZ (1) CZ282744B6 (no)
DE (2) DE4105480A1 (no)
DK (1) DK0500108T3 (no)
ES (1) ES2093122T3 (no)
FI (1) FI106029B (no)
GR (1) GR3021395T3 (no)
HU (1) HU214881B (no)
IE (1) IE920276A1 (no)
IL (1) IL101024A (no)
MX (1) MX9200709A (no)
NO (1) NO300329B1 (no)
NZ (1) NZ241570A (no)
ZA (1) ZA921230B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU9096001A (en) 2000-09-08 2002-03-22 Amgen Inc G-csf analog compositions and methods
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
DE60236522D1 (de) 2001-07-11 2010-07-08 Maxygen Inc G-csf konjugate
AU2003210052A1 (en) 2002-03-20 2003-09-29 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
RU2007149238A (ru) 2005-06-01 2009-07-20 Максиджен Холдингз Лтд. (Ky) Пегилированные полипептиды гксф и способы их получения
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2009023566A2 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en) 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
NZ601759A (en) 2010-03-17 2013-07-26 Biogenerix Gmbh Method for obtaining biologically active recombinant human g-csf
WO2011123570A2 (en) 2010-04-01 2011-10-06 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
JP6388581B2 (ja) * 2012-08-02 2018-09-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 単量体および多量体分子を生産するための方法およびその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
DK55685A (da) * 1985-02-07 1986-08-08 Nordisk Gentofte Enzym eller enzymkompleks med proteolytisk aktivitet
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US5082775A (en) * 1984-05-11 1992-01-21 Berlex Laboratories, Inc. Efficient process for isolating insoluble heterologous protein using non-ionic detergents
US4948729A (en) * 1985-03-25 1990-08-14 Cetus Corporation Production of soluble recombinant proteins
US4783415A (en) * 1985-03-28 1988-11-08 Meiji Seika Kabushiki Kaisha Gene coding for signal peptides and utilization thereof
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3636903A1 (de) * 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
EP0621340A1 (en) * 1987-03-20 1994-10-26 Creative Biomolecules, Inc. Product and process for the production and purification of recombinant polypeptides
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
EP0371041A1 (en) * 1987-06-24 1990-06-06 Novo Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
ZA901719B (en) * 1989-03-19 1991-01-30 Akzo Nv Hog cholera virus vaccine and diagnostics
US5191063A (en) * 1989-05-02 1993-03-02 University Of Medicine And Dentistry Of New Jersey Production of biologically active polypeptides by treatment with an exogenous peptide sequence
US5115102A (en) * 1989-07-21 1992-05-19 Monsanto Company Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
DE69126434D1 (de) * 1990-08-20 1997-07-10 Novo Nordisk As Prozess für die Herstellung von biologisch aktivem IGF-1 durch Verwendung von amino-terminal verlängertem IGF-1

Also Published As

Publication number Publication date
KR950014493B1 (ko) 1995-12-02
ZA921230B (en) 1992-11-25
CZ282744B6 (cs) 1997-09-17
EP0500108A3 (en) 1993-04-07
CS49992A3 (en) 1992-09-16
IE920276A1 (en) 1992-08-26
AU1094892A (en) 1992-08-27
IL101024A (en) 1996-06-18
MX9200709A (es) 1992-09-01
DK0500108T3 (da) 1997-03-24
NO300329B1 (no) 1997-05-12
JP2528232B2 (ja) 1996-08-28
FI920742A (fi) 1992-08-22
US5578710A (en) 1996-11-26
CA2061569C (en) 2000-10-24
HU214881B (hu) 1998-07-28
DE59207351D1 (de) 1996-11-21
JPH05244977A (ja) 1993-09-24
FI920742A0 (fi) 1992-02-20
HUT68021A (en) 1995-04-04
NZ241570A (en) 1994-09-27
ES2093122T3 (es) 1996-12-16
KR920016464A (ko) 1992-09-24
AU641081B2 (en) 1993-09-09
EP0500108A2 (de) 1992-08-26
NO920671L (no) 1992-08-24
CA2061569A1 (en) 1992-08-22
DE4105480A1 (de) 1992-08-27
NO920671D0 (no) 1992-02-20
ATE144284T1 (de) 1996-11-15
GR3021395T3 (en) 1997-01-31
EP0500108B1 (de) 1996-10-16
IL101024A0 (en) 1992-11-15
HU9200548D0 (en) 1992-04-28

Similar Documents

Publication Publication Date Title
FI106029B (fi) Yhdistelmä -DNA-teknisten proteiinien parannettu aktivointi
KR20070091131A (ko) 카복시-말단 아미드화 펩티드를 제조하는 방법
Zhang et al. Biological synthesis of monodisperse derivatives of poly (. alpha., L-glutamic acid): model rodlike polymers
Xu et al. High‐Level Expression of a Soluble Functional Antimicrobial Peptide, Human β‐Defensin 2, in Escherichia coli
CN114853881B (zh) 一种重组人源融合胶原蛋白及其高效羟基化方法与应用
CN111647089A (zh) 一种重组类人弹性蛋白及其组合物
CN112980865A (zh) 一种重组类人胶原蛋白工程菌的构建方法
CN107267537B (zh) 一种杂合抗菌肽mlh的制备方法
CA2206848A1 (en) Production of peptides using recombinant fusion protein constructs
JP5347255B2 (ja) 組換え蛋白質の可溶性蛋白質としての製造方法
CA2467142C (en) Improved method for the recombinant production of polypeptides
CN101608179B (zh) 融合肝素酶及其编码基因
EP1981978B1 (en) Affinity polypeptide for purification of recombinant proteins
RU2316590C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pE-His8-TrxL-Ar2, КОДИРУЮЩАЯ ГИБРИДНЫЙ БЕЛОК, СОДЕРЖАЩИЙ АНТИМИКРОБНЫЙ ПЕПТИД АРЕНИЦИН МОРСКОГО КОЛЬЧАТОГО ЧЕРВЯ Arenicola marina, И ШТАММ Escherichia coli BL21(DE3)/pE-His8-TrxL-Ar2 - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА, СОДЕРЖАЩЕГО АРЕНИЦИН
CN111073925B (zh) 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法
RU2441072C1 (ru) ГИБРИДНЫЙ БЕЛОК, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА И СПОСОБ ПОЛУЧЕНИЯ БЕЗМЕТИОНИНОВОГО ИНТЕРФЕРОНА АЛЬФА-2b ЧЕЛОВЕКА ИЗ ЭТОГО ГИБРИДНОГО БЕЛКА
CN101775404A (zh) 一种原核表达体系高表达碱性蛋白的方法
KR20080012437A (ko) 세포막투과 전달 펩타이드 및 이를 포함하는 생물제제
CN112661833A (zh) 重组人干扰素hIFN-κ基因工程菌株及其构建方法和用途
TW206236B (no)
JP4019145B2 (ja) 封入体フリーの組換えタンパク質を得る方法
CN114990097A (zh) L-天冬氨酸-α-脱羧酶突变体及其应用
CN114249839A (zh) 一种ⅲ型胶原蛋白的融合蛋白、表达系统、药物组合物及应用
RU2181771C1 (ru) Рекомбинантная плазмидная днк perpins1, кодирующая аминокислотную последовательность рекомбинантного проинсулина человека, и штамм escherichia coli bl21(de3)/perpins1-продуцент рекомбинантного человеческого проинсулина
CN112480224A (zh) 一类融合表达穿膜肽的海洋来源抗氧化蛋白及其制备方法与应用

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH

MA Patent expired